AbbVie Inc (ABBV)vsMacroGenics Inc (MGNX)
ABBV
AbbVie Inc
$261.74
+1.79%
HEALTHCARE · Cap: $454.36B
MGNX
MacroGenics Inc
$4.00
+0.76%
HEALTHCARE · Cap: $270.73M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 36662% more annual revenue ($64.39B vs $175.14M). ABBV leads profitability with a 9.8% profit margin vs -8.3%. MGNX appears more attractively valued with a PEG of 0.01. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
MGNX
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$261.74
$109.92 premium
Intrinsic value data unavailable for MGNX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Growing faster than its price suggests
Revenue surging 378.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -331.9% — below average capital efficiency
Earnings declined 70.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : MGNX
The strongest argument for MGNX centers on PEG Ratio, Revenue Growth. Revenue growth of 378.0% demonstrates continued momentum. PEG of 0.01 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : MGNX
The primary concerns for MGNX are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while MGNX is a hypergrowth play — different risk/reward profiles.
MGNX carries more volatility with a beta of 1.22 — expect wider price swings.
MGNX is growing revenue faster at 378.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 42/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
MacroGenics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?